Ascendiant Capital Markets Forecasts SXTP Q2 Earnings

60 Degrees Pharmaceuticals Inc. (NASDAQ:SXTP) – Analysts at Ascendiant Capital Markets dropped their Q2 2026 earnings estimates for shares of 60 Degrees Pharmaceuticals in a report issued on Wednesday, May 20th. Ascendiant Capital Markets analyst L. Ward now expects that the company will post earnings per share of ($0.89) for the quarter, down from their previous forecast of ($0.78). Ascendiant Capital Markets has a “Buy” rating and a $3.70 price objective on the stock. The consensus estimate for 60 Degrees Pharmaceuticals’ current full-year earnings is ($3.16) per share. Ascendiant Capital Markets also issued estimates for 60 Degrees Pharmaceuticals’ Q3 2026 earnings at ($0.85) EPS, Q4 2026 earnings at ($0.89) EPS, FY2026 earnings at ($3.45) EPS and FY2027 earnings at ($3.58) EPS.

Several other analysts have also weighed in on SXTP. Weiss Ratings reiterated a “sell (e+)” rating on shares of 60 Degrees Pharmaceuticals in a research report on Friday, March 27th. HC Wainwright lowered shares of 60 Degrees Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Wednesday, May 20th. Finally, Wall Street Zen lowered shares of 60 Degrees Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Sunday, April 12th. One investment analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $13.85.

60 Degrees Pharmaceuticals Stock Performance

Shares of 60 Degrees Pharmaceuticals stock opened at $1.41 on Thursday. The firm’s 50-day simple moving average is $1.68 and its 200-day simple moving average is $2.76. 60 Degrees Pharmaceuticals has a twelve month low of $1.29 and a twelve month high of $14.68. The firm has a market cap of $3.75 million, a P/E ratio of -0.16 and a beta of 2.69.

60 Degrees Pharmaceuticals (NASDAQ:SXTP) last issued its earnings results on Friday, May 15th. The company reported ($1.28) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.52). The firm had revenue of $0.16 million for the quarter, compared to analyst estimates of $0.44 million.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.